BioLife will increase the visible value of Bioscience resources worldwide by combining 3 automated systems for messaging, transaction processing and smart contracts into a digital ecosystem for the Bioscience industry.BioLife will build a global high-end biomedical resources DLT platform for products, services and data to provide safe, private, reliable, efficient and economical service access for biomedical resource owners, patients and investors.A consortium chain based on ACChain, BioLife is an on-chain asset digitization and private handler for patients, investors and owners of global biomedical resources. BioLife’s digital ecosystem is a distributed, adaptive, open-source, peer to peer system. Its blockchain properties of self-organization, scalability, interoperability and resilience were inspired by the very natural ecosystems from which Swiss Serolab derives its health care solutions. Distribution, circulation and service placement are the three basic applications of the BioLife digital ecosystem.
The BioLife Service Platform will provide digital portals for pharmaceutical companies, biomedical institutions and equipment manufacturers and use blockchain technology to record the entire process of the biomedical services supply chain, treatment processes and results. BioLife’s adoption of DLT as its technology backbone will introduce the following benefits to all areas of the biomedical services sector that are impacted by BioLife Data: heightened security and resistance to tampering, protection of personally identifiable information and other elements of privacy (including protection against data scrapes), elimination of any single point of failure and disintermediation of third parties (thereby reducing transaction times and eliminating third party transaction fees).
In the future, BioLife will be extended to smartwear for the daily collection of physical health data. It can achieve realtime monitoring and early warning of a patient’s physical health through artificial intelligence, machine learning and big data technology. At the same time, BioLife will also head in the direction of biomedical science and research, providing a large amount of sample data for scientific research institutions. This will establish a shared data platform among scientific research institutions, recording biomedical scientific research results to ensure the clarity of ownership and accurate return of scientific research results to reduce R&D duplication and to enjoy the fruitful results. BioLife is aiming to promote the progress and sustainable development of life science and technology.
Attention. There is a risk that unverified members are not actually members of the team
$194 839 197
This offer is based solely on information provided by the offeror and other publicly available sources.
The token sale or exchange event is completely independent of ICOholder. ICOholder is not involved in any way, including technical support or promotion.
We list token sales from entities with which we have no relationship to help users track overall activity within the token sector. This information is not intended as advice, and you should seek professional or specialist guidance or conduct your own due diligence before making any decisions based on our content.
Any terms and conditions regarding token acquisition are solely between contributors and the token issuer. ICOholder is not the seller of these tokens.
ICOholder is not legally responsible for any representations made by third parties about any token sale. Any claims for breach of contract must be directed against the listed token issuing entity.
If you have concerns about the nature, legality, or propriety of a token sale or the involved individuals, please contact email@example.com with detailed information.